PPARG and acute myeloid leukemia: Taken together, the results obtained from this study shed light on the importance of PPARG in the treatment strategies of AML and suggested that the stimulation of this nuclear receptor using pioglitazone may provide a promising outcome for patients suffering from non‐M3 AML.